相关实验视频

Updated: Jan 14, 2026

Author Spotlight: Generating Neuronal Phenotypic Profiles - A Protocol to Culture and Image Human Midbrain Dopaminergic Neurons

Author Spotlight: Generating Neuronal Phenotypic Profiles - A Protocol to Culture and Image Human Midbrain Dopaminergic Neurons

Published on: July 7, 2023

发生性帕金森病中的淋巴功能:与症状的关联,灰质体积和光转化风险

Amei Chen¹, Zhanyu Kuang¹, Pek-Lan Khong²

¹Department of Radiology, Guangzhou First People's Hospital Affiliated to Guangzhou Medical University, the Second Affiliated Hospital of South China University of Technology, Guangzhou, China.

European journal of neurology

|October 25, 2025

概括

淋巴功能障碍,通过沿周脉空间 (DTI-ALPS) 指数的扩散张力成像测量,在前兆帕金森病 (pPD) 中减少. 这种减少与患帕金森病的风险增加有关.

科学领域:

神经成像是一种神经成像.
神经退行性疾病神经退行性疾病
脑脊液动力学脑脊液动力学

背景情况:

在帕金森病 (PD) 中观察到淋巴系统功能障碍.
淋巴系统在预发性PD (pPD) 中的状态尚不清楚.
沿周血管空间 (DTI-ALPS) 的扩散张力成像指数作为淋巴功能间接测量.

研究的目的:

用DTI-ALPS指数评估PPD队列中的淋巴相关变化.
调查DTI-ALPS指数与PPD中的临床症状之间的关联.
探索DTI-ALPS指数与pPD中的灰质体积之间的关系.
确定DTI-ALPS指数是否可以预测PPD中的转换风险.

主要方法:

分析来自帕金森病进展标志物倡议 (PPMI) 队列的数据.
包括51名健康对照 (HC),83名pPD患者和202名新发PD患者 (dnPD).
跨组的DTI-ALPS指数的横截面比较和与PPD中的临床/成像数据的相关性.
使用卡普兰-梅尔和考克斯回归在≥4年随访期间对DTI-ALPS指数和表转换风险的纵向评估.

主要成果:

与HC相比,在pPD和dnPD观察到显著降低的DTI-ALPS指数 (p < 0.001).与HC相比,在pPD和dnPD观察到显著降低的DTI-ALPS指数 (p < 0.001).
在PPD中,较低的DTI-ALPS指数与增加的焦虑,较高的CSF p-tau和t-tau以及改变的灰色物质体积 (极,乳头,状圈,后部中枢圈) 相相关.
在DTI-ALPS指数下降一个标准偏差增加了13%的现象转换到PD的风险 (调整HR=0.87,p=0.018).

结论:

在PPD中降低DTI-ALPS指数表明潜在的淋巴功能障碍.
在PPD中改变的淋巴功能与转换的风险增加有关.
DTI-ALPS指数与PPD的临床症状和结构性大脑变化相关.

关键词:

帕金森病的疾病.扩散张力成像扩散张力成像疾病的进展疾病的进展淋巴系统淋巴系统产生突发症状的症状

更多相关视频

Targeting Alpha Synuclein Aggregates in Cutaneous Peripheral Nerve Fibers by Free-floating Immunofluorescence Assay

Targeting Alpha Synuclein Aggregates in Cutaneous Peripheral Nerve Fibers by Free-floating Immunofluorescence Assay

Published on: June 25, 2019

A Gravity-Fed Transcardial Perfusion Method for Histologic Analysis of the Mouse Central Nervous System

A Gravity-Fed Transcardial Perfusion Method for Histologic Analysis of the Mouse Central Nervous System

Published on: January 21, 2022

相关概念视频

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...

Neural Regulation

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...

Lysosomal Hydrolases

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...